ClinicalTrials.gg
TerminatedNCT02733614Updated Nov 1, 2021

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

A Phase 2 interventional study of SRX246 and Placebo in PTSD, sponsored by Azevan Pharmaceuticals. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-11-01.

Sponsored by Azevan Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
1,060th of 1,491
33 · median 65
Started
2016
with 71 others
Phase 2
168 of 1,664
38 open now
Registered
680th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 1,060th largest by enrollment of the 1,491 interventional ones that give a count, is one of 72 that started in 2016, is one of 168 in phase 2, and was the 680th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

18-week, crossover, double-blind, randomized, placebo controlled proof-of-concept study to assess the efficacy and safety of SRX246 (160 mg bid) vs placebo in 52 adult veterans and civilians with a primary diagnosis of PTSD. Subjects will be randomly assigned in a double-blind fashion to 2 groups in a crossover design. The first group will receive SRX246 for 8 weeks followed by 8 weeks of placebo, while the second group will receive placebo for 8 weeks followed by 8 weeks of SRX246. Both groups will engage in a 7-day washout period between treatments. Subjects will be assessed at baseline and then every 2 weeks during the trial using the CAPS.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable, current diagnosis of PTSD

Exclusion criteria

Exclusion Criteria:

  • Medically unstable
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    SRX246

    SRX246 160 mg BID, oral administration, capsules, daily for 8 weeks

    Drug: SRX246

  • Placebo comparator
    Placebo

    oral administration, capsules, daily for 8 weeks

    Drug: Placebo

Interventions

  • DrugSRX246

    novel V1a receptor antagonist

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Assessment of overall clinical improvement

    Measured using the Clinician Administered PTSD Scale (CAPS)

    Time frame: 18 weeks

Secondary outcomes

  1. Number of participants with treatment-related adverse events

    Assessments of adverse events (AEs), dose reductions and dropouts due to AEs

    Time frame: 18 weeks

  2. Reduction in depressive symptoms

    Measured using the Beck Depression Inventory (BDI)

    Time frame: 18 weeks

  3. Reduction in anger and aggression

    Measured using the Overt Aggression Scale-Modified (OAS-M)

    Time frame: 18 weeks

  4. Reduction in irritability

    Measured using the Sheehan Irritability Scale (SIS)

    Time frame: 18 weeks

  5. Improvement in overall functioning

    Measured using the Medical Outcomes Study Short-Form 12-Item Health Survey (SF-12)

    Time frame: 18 weeks

  6. Improvement in quality of life

    Measured using the Sheehan Disability Scale (SDS)

    Time frame: 18 weeks

  7. Improvement in sleep quality

    Measured using the Pittsburgh Sleep Quality Index (PSQI)

    Time frame: 18 weeks

07

Study locations

1 site
  • Weill Cornell Medical College
    New York, New York 10065, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Oct 2020, 46 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2016
First posted
Apr 11, 2016
StartActual
Dec 2016
Primary completionActual
Oct 2020
CompletionActual
Mar 31, 2021
Last update
Nov 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02733614
Lead sponsor
Azevan Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 11, 2016
Start date
Dec 2016
Primary completion
Oct 2020
Completion
Mar 31, 2021
Last update
Nov 1, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRX246

Start the discussion